Compare · A vs RPID
A vs RPID
Side-by-side comparison of Agilent Technologies Inc. (A) and Rapid Micro Biosystems Inc. (RPID): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both A and RPID operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- A is the larger of the two at $43.71B, about 525.0x RPID ($83.3M).
- RPID has hit the wire 4 times in the past 4 weeks while A has been quiet.
- A has more recent analyst coverage (25 ratings vs 10 for RPID).
- Company
- Agilent Technologies Inc.
- Rapid Micro Biosystems Inc.
- Price
- -
- -
- Market cap
- $43.71B
- $83.3M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1999
- 2021
- News (4w)
- 0
- 4
- Recent ratings
- 25
- 10
Agilent Technologies Inc.
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid and gas chromatography systems and components; liquid and gas chromatography mass spectrometry systems; inductively coupled plasma mass and optical emission spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate readers; laboratory software, information management, and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment, genetic data management, and interpretation support software; and equipment to produce synthesized oligonucleotide. It also offers immunohistochemistry, in situ hybridization, and hematoxylin and eosin staining and special staining; instruments, consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. It has collaboration agreement with SGS AXYS. The company was incorporated in 1999 and is headquartered in Santa Clara, California.
Latest A
- Agilent Research Catalyst Award Presented to Eastern Institute of Technology, Ningbo
- Agilent to Announce Third-Quarter Fiscal Year 2026 Financial Results on Aug. 26
- Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
- Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma
- Jefferies resumed coverage on Agilent with a new price target
- Agilent Expands Altura Portfolio with Inert Size Exclusion and PLRP-S Columns for Biotherapeutic Analysis
- Agilent Launches AI-Driven Analysis Module for Agilent xCELLigence RTCA eSight
- Senior Vice President Kirkwood Jonah Prevost covered exercise/tax liability with 30 shares, decreasing direct ownership by 0.21% to 14,108 units (SEC Form 4)
- Bernstein resumed coverage on Agilent with a new price target
- Agilent Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
Latest RPID
- SEC Form 10-Q filed by Rapid Micro Biosystems Inc.
- Rapid Micro Biosystems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Rapid Micro Biosystems Reports Second Quarter 2026 Financial Results
- Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Director Kollender Richard S exercised 3,508 shares at a strike of $0.75, increasing direct ownership by 3% to 133,826 units (SEC Form 4)
- PRESIDENT AND CEO Spignesi Robert G. Jr. exercised 1,402 shares at a strike of $0.75, increasing direct ownership by 0.12% to 1,191,973 units (SEC Form 4)
- Rapid Micro Biosystems to Announce Second Quarter 2026 Financial Results on August 7, 2026
- Rapid Micro Biosystems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Director Lowenstein Inese was granted 12,787 shares, increasing direct ownership by 22% to 70,687 units (SEC Form 4)
- Director Pei Melinda Litherland was granted 12,787 shares, increasing direct ownership by 15% to 100,687 units (SEC Form 4)